Информационные технологии мониторинга и анализа отдаленных результатов терапии больных хроническим миелолейкозом
Диссертация
Терапия хронического миелолейкоза (XMJI) — клонального миелопролиферативного заболевания со специфическим маркером Ph'-хромосомой, во второй половине 20 века была направлена, в основном, на контроль над массой лейкемических клеток крови. Перспективу увеличения продолжительности жизни по сравнению с ранее применявшимися цитотоксическими средствами для большинства больных давали интерферон-альфа… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- ГЛАВА 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Структура химерного гена ВСЫ-АВЬ и его роль в развитии хронического миелолейкоза
- 1. 2. Диагностика и характеристика фаз хронического миелолейкоза
- 1. 3. Терапия хронического миелолейкоза: способы достижения гематологической и цитогенетической ремиссии
- 1. 3. 1. Терапевтические подходы до эры ингибиторов тирозинкиназ
- 1. 3. 2. Иматиниба мезилат в лечении хронического миелолейкоза
- 1. 3. 3. Факторы, влияющие на достижение полного цитогенетического ответа при терапии иматинибом
- 1. 4. Диагностика резистентности к иматиниба мезилату
- 1. 4. 1. Критерии резистентности к иматиниба мезилату
- 1. 4. 2. Механизмы резистентности к иматинибу
- 1. 5. Ингибиторы тирозинкиназ второго поколения
- 1. 5. 1. Рекомендации по лечению хронической фазы хронического миелолейкоза ингибиторами тирозинкиназ второго поколения
- 1. 6. Регистры, базы данных в медицине
- 1. 6. 1. Информационные процессы, основные понятия
- 1. 6. 2. Базы данных. Классификации. Принципы построения
- 1. 6. 3. Медицинские регистры
- 1. 6. 4. Регистр больных хроническим миелолейкозом в России
- 2. 1. Технические характеристики регистра
- 2. 2. Статистическая обработка данных
- 2. 3. Характеристика выборки исследования
- 2. 3. 1. Характеристика больных в поздней хронической фазе хронического миелолеикоза.^'
- 2. 3. 2. Принципы терапии ингибиторами тирозинкиназ
- 2. 3. 3. Оценка эффективности терапии ингибиторами тирозинкиназ
- 3. 1. Этапы модернизации информационной структуры Регистра больных хроническим миелолейкозом
- 3. 2. Структура информационной структуры Регистра больных хроническим миелолейкозом
- 3. 3. Разделы «карты пациента» Регистра больных хроническим миелолейкозом
- 3. 4. Регистр больных хроническим миелолейкозом- база для проведения научных исследований
- 4. 1. Характеристика терапии ингибиторами тирозинкиназ
- 4. 2. Эффективность терапии иматинибом
- 4. 2. 1. Гематологический ответ. Оценка прогностического значения достижения полного гематологического ответа к 3 и 6 месяцам терапии иматинибом
- 4. 2. 2. Цитогенетический ответ
- 4. 3. Выживаемость больных в хронической фазе хронического миелолейкоза при лечении ингибиторами тирозинкиназ
Список литературы
- Волкова М.А. 50 лет современной терапии хронического миелолейкоза, материалы VII Росс. Онкологической конференции, Москва, 2003.
- Волкова М.А. Гливек первый препарат патогенетического действия в терапии хронического миелолейкоза. Журнал современная онкология, экстравыпуск, М.- 2003, стр. 5−10.
- Волкова М.А. Хронический миелолейкоз. Клиническая онкогематология. Под ред. М. А. Волковой. М., Медицина, 2001, с.237−262
- Воробьев А.И., Бриллиант М. Д. «Хронический миелолейкоз». В сб. Руководство по гематологии. М., Медицина, 1985, т.1, с.234−243
- Дейт К. Дж. Введение в системы баз данных. — 8-е издание: пер. с англ.-М.: Издательский дом «Вильяме», 2005- 1312с, с.52- с.62−64
- Дружкова Г. А. Ингибитор bcr/abl- тирозинкиназы в лечении больных хроническим миелолейкозом, резистентных к интерферону-а. Автореферат канд. дисс., М, — 2005
- Кадеев Д.Н. Информационные технологии и электронные коммуникации. Курс лекций.
- Козинец Г. И. Атлас клеток крови и костного мозга М: Изд."Триада-Х", 1998- 160с., с.56
- Краткий философский словарь под ред. А. П. Алексеева. 2-е изд., перераб. и доп. — М.: ТК Велби, Изд-во Проспект, 2006. — 496 с.-с.217.
- Курова Е.С. Клиническая эффективность молекулярно-направленной терапии в фазе акселерации хронического миелолейкоза. Автореф. канд. дис. М., 2003.-c.21.
- Национальный стандарт Российской Федерации" ГОСТ Р ИСО МЭК ТО 10 032−2007. Эталонная модель управления данными. М: ФГУП «Стандартинформ».- 2009- 40с, с.7
- Новый иллюстративный энциклопедический словарь / под ред. В. И. Бородулина, А. П. Горкина и др. М.: Большая Российская энциклопедия, 2003.-912 с. -С.450.
- Приказ от 23 декабря 1996 г. № 420 о создании Государственного ракового регистра.
- Туркина А.Г. Ингибитор сигнальных путей STI 571 (Signal Transductor Inhibitor) новое направление в лечении хронического миелолейкоза Современная онкология.- 2001.- т. 3, № 2.
- Туркина А.Г. Клиническое значение молекулярно-генетических и иммуно-фенотипических характеристик хронического миелолейкоза. Автореферат дисс. д-ра мед. наук. М.-1998
- Туркина А.Г., Н.Д. Хорошко, С. С. Круглов с соавторами. Практические рекомендации по лечению больных хроническим миелолейкозом. (Пособие для врачей).- М.- 2005.
- Туркина А.Г., Хорошко Н. Д., Дружкова Г. А. с соавторами. Эффективность терапии иматиниб мезилата (Гливека) у больных в хронической фазе хронического миелолейкоза. Тер архив.- 2003- 75(8):62−67.
- Хорошко Н.Д. Интенсификация терапии хронического миелолейкоза с учетом факторов прогнозирования течения болезни. Тер. архив.- 1993- 7: 23−28
- Abram С., Courtneidge S. Src family tyrosine kinases and growth factor signaling. Exp Cell Res.- 2000- 254(1):1−13.
- Allan N., Richards S., Sheperd P. et al. UK Medical Research Council randomized multicenter trial of interferon-alfa in chronic myeloid leukemia: improved survival irrespective of cytogenetic response.// The Lancet.- 1995.- v. 345, p 1392−97.
- Antonelli G., Currenti M., Turriziani O. et al. Neutralising antibodies to interferon a: relative frequency in patients with different interferon preparations. J. Inf. Dis.- 1991- 163: 883 885.
- Apperley J. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol.- 2007- 8(11): 1018−1029.
- Azam M., Latek R., Daley G. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cancer Cell.-2003- 112(6):831−843.
- Baccarani M. et al. Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. JClin Oncol.- 2009- 27:6041−6051.
- Baccarani M., Russo D., Rosti G. et al. Interferon-alfa for chronic myeloid leukemia. Semin. Hematol.- 2003- 40: 22−33.
- Baccarani M., Saglio G., Goldman J. et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood.- 2006- 108(6): 18 091 820.
- Bonifazi F., De Vivo A., Rosti G. et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood.- 2001- 98: 3074−81.
- Branford S., Cross N., Hochhaus A. et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia.- 2006- 20(11):1925−1930.
- Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A.- 2005- 102(31):11 011−11 016.
- Cervantes F. On behalf of the IRIS study group. Durability of responses to imatinib in newly diagnosed chronic-phase chronic myeloid leukemia (CML): 24-month update from the IRIS Study. Blood.- 2003- 102:181a.
- Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration, Drug Approval Summary: conversion of Imatinib Mesylate (STI571- Gleevec) tabletsfrom accelerated approval to full approval. Clinical Cancer Research 2005-ll (l):12−9.
- Collins S., Coleman H., Groudine M. Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells. Mol. and Cel. Biol.- 1987- 7: 28 702 876.
- Corbin AS, La Rosee P, Stoffregen EP, et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood.- 2003- 101(11):4611−4614.
- Cortes J., Jabbour E., Kantarjian H. et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood.- 2007- 110(12):4005−4011.
- Cortes J., Talpaz M., O’Brien S. et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer.- 2003- 98: 1105−13.
- Cortes J. et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood.- 2007- 109, 3207−3213.
- Crossman L., Druker B., Deininger M. et al. hOCT 1 and resistance to imatinib. Blood. 2005- 106(3): 1133−1134
- Daley GQ, Van Etten RA, Baltimore D. Introduction of chronic myelogenous leukemia in mice by the p210 bcr-abl gene of the Philadelphia chromosome. Science 1990- 247:824−830.
- De Breaklleer D. Cytogenet. Cell. Genet.- 1987- vol.44.-p.215−218.
- Deininger M., Buchdunger E., Druker B. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood.- 2005- 105(7): 26 402 653.
- Deininger M. Chronic myeloid leukemia. Management of early stage disease// J. Hematology. Am. Soc. Hematol 2005- p. 174−182.
- Deininger M., O’Brien S., Ford J. et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol.- 2003- 21:16 371 647.
- Druker B. J, Tamura S, Buchdunger E et al. Effects of selective inhibitor of the ABL tyrosine kinase on the growth of Bcr-ABL positive cells. Nat Med 1996- 2: 561−566.
- Druker B. STI571 (Gleevec/Glivec, imatinib) versus interferon (INF)+ cytarabine as initial therapy for patients with CML for the IRIS Study Group: results of a randomized study. Program/Proceeding ASCO.- 2002- 21: part 1, p. la, No 1
- Druker B., Guilhot F., O’Brien S. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med.- 2006- 355(23): 24 082 417.
- Faderl S., Talpaz M., Estrov Z. Chronic myelogenous leukemia: biology and therapy. Ann Int Med. 1999.- v. 131.- 207−219.
- Gaiger A., Henn T., Horth E. et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood.- 1995- 86(6):2371−2378.
- Gambacorti-Passerini C. et al. Imatinib Long Term Effects (ILTE) Study: An Independent, International Study in CML Patients. Blood (ASH Annual Meeting Abstracts).- Nov 2008- 112: 1099.
- Gambacorti-Passerini C., Gunby R., Piazza R. et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol.- 2003−4(2):75−85.
- Geary C. The story of chronic myeloid leukemia. Br J Haematol.- 2000- 110:211.
- Goldman J. Management of chronic myeloid leukemia. Semin. Hematol.-2003−40:1−103.
- Goldman J., Melo J. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med.- 2003- 349: 1451−64.
- Gorre M., Mohammed M., Ellwood K. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science.-2001- 293(5531):876−880.
- Griswold I., MacPartlin M., Bumm T. et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol.- 2006- 26(16): 6082−6093.
- Guilhot F., Chastang C., Michallet M. et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med.- 1997.- 337:223
- Guilhot F., Roy L., Millot F. Update of first-line in chronic phase chronic myeloid leukemia. Hematology, education program of the 11 congress of EHA, Amsterdam, the Netherlands, June 15−18, 2006. p. 93−97.
- Hahn E. The quality of life of patients with chronic phase chronic myeloid leukemia in the IRIS study of interferon-alpha plus ara-c vs imatinib (STI571, Glivec). The Hematol J.- 2002- 3: (1014 suppl. l): 300.
- Hantschel O., Nagar B., Guettler S. et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell.- 2003−112(6):845−857.
- Hasford J., Pfirrmann M., Hehlmann R. et al. A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon- alfa. J Nat. Cancer Inst.- 1998- 90: 850−58.
- Hehlmann R., Heimpel H., Hasford J. et al. Randomized comparison of interferon-alfa with busulfan and Hydroxyurea in chronic myelogenous leukemia. Blood.- 1994.- v. 84, N 12, p. 4064−4077.
- Heisterkarap N., Stam K, Groffen J. Structural organization of the bcr gene and its role in the Ph I translocation. Nature.- 1985.- 315:758−761.
- Hochhaus A., La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia.- 2004−18(8):1321−1331.
- Hughes T., Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev.- 2006- 20(1):29−41.
- Hughes T., Kaeda J, Brandford S, et al: Frequency of major molecular response to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med.- 2003.- 349:14 231 432
- Hunderford D., Donelli A., Nowell P. Chromosome studies in human leukemia// Hum. Genet.- 1959.- vol.6 l-p.696−671.
- Huntly B., Bench A., Green A. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood.-2003- 102:1160−68.
- Jabbour E., Kantarjian H., Jones D., et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with Imatinib mesylate. Leukemia.- 2006- 20(10): 1767−1773.
- Jackson P., Baltimore D://N-teriminal mutation activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J.- 1989- 8:449.
- Jayson G. et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J. Clin. Oncol.- 2005.-23, 973−981
- Jennings B., Mills K. C-myc locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leuk Res.- 1998- 22(10):899−903.
- Johansson B., Fioretos T., Mitelman F. Cytogenetic and molecular genetics evolution of chronic myeloid leukemia. Acta Haematol.- 2002−107(2):76−94.
- Kantarjian H., Cortes J. Testing the prognostic model of Marin et al. in an independent chronic myelogenous leukemia study group. Leukemia.-2004- 18:650.
- Kantarjian H., O’Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer.- 2003- 97:1033−41.
- Kantarjian H., Sawyers C., Hochhaus A. et al. International STI571 CML Study Group: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med.- 2002−346:645−652.
- Kantarjian H., Sawyers C., Hochhaus A. et al. A phase II study of STI 571, a tyrosine kinase inhibitor, in patients with resistant or refractoiy Philadelphia chromosome positive chronic myeloid leukemia. Blood, 2000: 96:470a.
- Kantarjian H., Smith T., O’Brien S. et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med.- 1995.-122:254
- Kantarjian H., Talpaz M., O’Brien S. et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin. Cancer Res.- 2002- 8: 2177−87.
- Kantarjian H., Talpaz M. Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia. Semin Oncol.- 1994- 21(6 Suppl 14):8−13.
- Kantarjian H. et al. Nilotinib' in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542−2551 (2006).
- Kerkhoff E., Rapp U. Cell cycle targets of Ras/Raf signaling. Oncogene.- 1998- 17(11 Reviews): 1457−1462.
- Khorashad J., Anand M., Marin D. et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to Imatinib. Leukemia.- 2006- 20(4):658−663.
- Kim D. et al. Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients. Blood (ASH Annual Meeting Abstracts).- 2009- 114: # 2199.
- Komarova N., Wodarz D. Effect of cellular quiescence on the success of targeted CML therapy. PLoS ONE.- 2007- 2(10):e990.
- Konopka J., Witte O. Activation of the abl oncogene in murine and human leukemias. Biochimica et Biophysica Acta.- 1985.- v 823: 1−17
- Krause D., van Etten R. Tyrosine kinases as targets for cancer therapy. N Engl J Med.-2005- 353: 172−87.
- Le Coutre P., Kreuzer K., Purshe S. et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother. Pharmacol.-2004- 53(4): 313−323.
- Le Coutre P. et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinibresistant and-intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). Blood.- 2006.- 108,53a.
- Lowenberg B. Minimal residual disease in chronic myeloid leukemia. N Engl J Med. 2003- 349(15):1399−1401.
- Mahon F., Deininger M., Schultheis B. et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood.- 2000- 96(3):1070−1079.
- Manley P., Cowan-Jacob S., Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl Kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. Acta.- 2005- 1754: 3−13.
- Marin D., Marktel S., Bua M, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon- alfa. Leukemia 2003- 17:1448−53.
- Marin D., Marktel S., Bua M. et al. The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations. Haematologica.- 2002- 87:980−989.
- Marin D., Milojkovic D., Olavarria E. et al: European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood.-2008.-112:4437−4444.
- McGahon A., Bissinnete B., Schmitt M. et al. BCR-ABL Maintains Resistence of Chronic Myeloid Leukemia Cells to Apoptosis Cells Death.- Blood.- 1994.83: 1179−87.
- Melnick J. et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc. Natl Acad. Sci USA.- 2006.-103, 3153−3158.
- Michor F., Hughes T., Iwasa Y. et al. Dynamics of chronic myeloid leukaemia. Nature.- 2005- 435(7046): 1267−1270.
- Milojkovic D., Nicholson E., Jane F. et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica.- Feb. 2010- 95: 224−231.
- Nagar B., Bornmann W., Pellicena P. et al. Crystal structures of the kinase domain of c-abl in complex with the small molecule inhibitors PD 173 955 and imatinib (STI-571). Cancer Res.- 2002- 62 (15): 4236−43.
- Nosaka T., Kawashima T., Misawa K. et al. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J.-1999- 18(17):4754−4765.
- Nowell P., Hungerford D. A minute chromosome in human chronic granulocytic leukemia. J. of the National Cancer Institute.- 1960.-25: 85−109.
- O’Hare T., Walters D., Stoffregen E. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-3 54 825 against clinically relevant imatinibresistant Abl kinase domain mutants. Cancer Res. 2005- 65(ll):4500−4505.
- O’Hare T., Eide C., Deininger M. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood.- 2007- 110(7): 2242−9.
- Protocol 3160A4−200-WW. A phase ^ Study of SKI-606 in Philadelphia Chromosome positive leukemias.
- Quintas-Cardama A., Cortes J. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006- 81(7):973−988.
- Raanani P., Ben-Bassat I., Gan S. et al. Assessment of the response to imatinib in chronic myeloid leukemia patients: Comparison between the FISH, multiplex, and RT-PCR methods. Eur J Haematol.- 2004.- 73:243−250.
- Reinhold U., Henning E., Leiblein S. et al. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white bone marrow cells in CML patients treated with imatinib. Leukemia.- 2003.- 17:1925−1929.
- Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer.- 2005- 5: 172−83.
- Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature.-1973.- vol.243 .-p.290−293.
- Sacchi S., Cortes J. et al. Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia. Hematology and Molecular Hematology 1997−11 (l):41−47.
- Sawyers C., Hochhaus A., Feldman E. et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002:99:3530−3539.
- Schinder T. et al., Structural mechanism for STI 571 inhibition of abelson tyrosine kinas. Science 2000.- 289: 1938.
- Shah N., Nicoll J., Nagar B. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell.- 2002- 2(2):117−125.
- Shtivelman E., Lifshitz B., Gale R. Alternative splicing of RNAs transcribed from human abl gene and from the bcr/abl fused gene. Cancer cell.-1986.-47: 277−284.
- Shtivelman E., Lifshitz B., Gale R. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Natur.- 1985.-315:550.
- Skaggs B., Gorre M., Ryvkin A., et al. Phosphorylation of the ATPbinding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc April 2009, Vol. 16, No. 2 Cancer Control 131 Natl Acad Sci USA. 2006−103(51):19 466−19 471.
- Sneed T., Kantarjian H., Talpaz M., et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer.- 2004- 100:116−21.
- Sokal J.E. Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment. Baillieres Clin Haematol 1987- 1: 907−29.
- Sonta S., Sandberg A. Chromosomes and causation of human cancer and leukemia. XXIV. Unusual and complex Phi translocations and their clinical significance. Blood.- 1977.-vol.50-p.691−697.
- Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine.- 2006−354:2531−2541.
- Talpaz M., Silver R., Druker B. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002.- 99:1928−37.
- The Benelux CML Study Group: Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon for chronic myeloid leukemia. Blood.- 1998.-91:2713,
- The Italian Cooperative Study Group on Chronic Myelogenous Leukemia. Interferon Alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.- New England Journal of Medicine.-1994, v. 330, p. 820−825.
- Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood.- 2004- 104(12): 3739−3745. (Epub 2004 Aug 17.)
- Verma D. et al. Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies. Blood (ASH Annual Meeting Abstracts), — Nov 2008- 112: 2125.
- Verstovsek S. et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.- 2006.- Leukemia Res. 30, 1365−1370.
- Weisberg E., Manley P., Breitenstein W. et al. Characterization of AMN 107, a selective inhibitors of wild-type and mutant Bcr-Abl.- Cancer Cell.- 2005- 7:129−141.
- Wu J., Meng F., Lu H. et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.- Blood.- 2008- 111(7):3821−3829.